Wanbury has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs). For Diphenhydramine HCl, the company has submitted DMF to Malaysia and Singapore. The company has proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. The company has also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
